Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 1998

View Archived Issues

MK-966 improves physical ability and quality of life in patients with OA, RA

New Maxamine data to be presented at annual symposium

Study completed on new therapy for traveler's diarrhea

Study shows Zadaxin plus chemotherapy inhibits cancerous tumors in mice

Myriad Genetics and Monsanto collaborate on drug target discovery

Amgen: Q3 1998 highlights

Cytel receives FDA grant to further development of selectin inhibitor

Axis Genetics enters collaboration for edible plant vaccine development

Vical provides clinical update of Allovectin-7 in treatment of head and neck cancer

Triangle Pharmaceuticals presents preliminary data on FTC in HBV patients

Novel MMP inhibitor synthesized at Abbott shows potent antitumor activity in vivo

New osteoarthritis treatment candidate blocks cartilage degradation

SB pursues CCR5 antagonists for the treatment of inflammation

MMP inhibitor BMS-453 improves disease symptoms in mice with experimental arthritis

Synthesis and use of novel ET-antagonist series disclosed by Merck KGaA

5-HT antagonists in development at Synthelabo for cardiovascular and other disorders

Novel antibody with potential in treating RA investigated by Santen

Synthelabo discloses orally active human thrombin inhibitors

Vanadocene complexes exert potent spermicidal effects in vitro; further study recommended

Potent and selective 5-HT1A/5-HT1B/5-HT1D receptor antagonists discovered at Pierre Fabre

New thiazolidinediones for diabetes reported in patent literature by Boehringer Mannheim

Abbott reports in vitro and in vivo antimycobacterial activity of new 2-pyridone

Lamivudine highlighted at recent Study for Liver Diseases meeting

Dutasteride outshines finasteride in BPH Rx

Animal data suggest that GPI-1046 may be useful in glaucoma

New flu pill helps patients quickly return to normal, improving health, sleep and activity

NIAID reports important reduction in latently infected cell pool in patients on HAART + IL-2

FDA advisory committee issues positive statement on DepoCyt

Igmesine: mode of action and preclinical antidepressant activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...